Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

milademetan (RAIN-32)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Daiichi Sankyo, Pathos, Rigel

Drug class:

MDM2 inhibitor

Related drugs:

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
MDM2 amplification	Sarcoma	MDM2 amplification	Sarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
GATA3 mutation	Hormone Receptor Positive Breast Cancer	GATA3 mutation	Hormone Receptor Positive Breast Cancer	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification + TWIST1 amplification	Sarcoma	MDM2 amplification + TWIST1 amplification	Sarcoma	RAIN-32 Sensitive: C3 – Early Trials RAIN-32 Sensitive : C3	RAIN-32 Sensitive: C3 – Early Trials RAIN-32 Sensitive : C3
MDM2 amplification + TP53 wild-type + TWIST1 amplification	Sarcoma	MDM2 amplification + TP53 wild-type + TWIST1 amplification	Sarcoma	RAIN-32 Sensitive: C3 – Early Trials RAIN-32 Sensitive : C3	RAIN-32 Sensitive: C3 – Early Trials RAIN-32 Sensitive : C3
FLT3-ITD mutation + FLT3 D835Y	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 D835Y	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: D – Preclinical quizartinib + RAIN-32 Sensitive : D	quizartinib + RAIN-32 Sensitive: D – Preclinical quizartinib + RAIN-32 Sensitive : D
FLT3-ITD mutation + FLT3 F691L	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 F691L	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: D – Preclinical quizartinib + RAIN-32 Sensitive : D	quizartinib + RAIN-32 Sensitive: D – Preclinical quizartinib + RAIN-32 Sensitive : D
TP53 wild-type	Merkel Cell Carcinoma	TP53 wild-type	Merkel Cell Carcinoma	RAIN-32 Sensitive: D – Preclinical RAIN-32 Sensitive : D	RAIN-32 Sensitive: D – Preclinical RAIN-32 Sensitive : D
MDM2 amplification	Hormone Receptor Positive Breast Cancer	MDM2 amplification	Hormone Receptor Positive Breast Cancer	RAIN-32 Sensitive: D – Preclinical RAIN-32 Sensitive : D	RAIN-32 Sensitive: D – Preclinical RAIN-32 Sensitive : D
KRAS G12S	Lung Adenocarcinoma	KRAS G12S	Lung Adenocarcinoma	trametinib + RAIN-32 Sensitive: D – Preclinical trametinib + RAIN-32 Sensitive : D	trametinib + RAIN-32 Sensitive: D – Preclinical trametinib + RAIN-32 Sensitive : D